Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases
Jonathan Mitchell(AstraZeneca (Australia)), Margarete A. Fabre(University of Cambridge), Joseph Vijai(Memorial Sloan Kettering Cancer Center), Ali Abbasi(Shahroud University of Medical Sciences), Mark M. Pomerantz(Dana-Farber Cancer Institute), Pablo Kuri‐Morales(Universidad Nacional Autónoma de México), David B. Goldstein(Electronic BioSciences (United States)), Jonathan Emberson(University of Oxford), Jason Torres(University of Chicago), Abhishek Nag(King's College London), Carolina Haefliger(AstraZeneca (United Kingdom)), Oliver S. Burren(AstraZeneca (United Kingdom)), Patrick R. Shea(Columbia University), Athena Matakidou(AstraZeneca (Sweden)), Ryan S. Dhindsa(Baylor College of Medicine), Lorelei A. Mucci(American Cancer Society), Jesús Alegre-Díaz(Universidad Nacional Autónoma de México), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Philip W. Kantoff(Convergent Science (United States)), Anthony W. Zoghbi(Baylor College of Medicine), Jacob E. Berchuck(Dana-Farber Cancer Institute), Jaime Berúmen(Yale University), Ruth March(AstraZeneca (United Kingdom)), Lauren Anderson-Dring(AstraZeneca (United Kingdom)), Quanli Wang, Niedzica Camacho(AstraZeneca (United Kingdom)), Brian Dougherty(AstraZeneca (United States)), Rory Collins(University of Oxford), Roberto Tapia‐Conyer(Universidad Nacional Autónoma de México), Slavé Petrovski(AstraZeneca (United Kingdom)), Amanda O’Neill(AstraZeneca (Brazil)), Vaidehi Jobanputra(Columbia University Irving Medical Center), Keren Carss(AstraZeneca (United Kingdom))
Cited by 4
Related Papers
Finding the missing heritability of complex diseases
|Nature|2009|8.5k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k